retatrutide triple agonist glp1 gip glucagon ly3437943 glp-1 mechanism Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Eli Lilly just announced striking
Pay in 4 interest-free payments of $6.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5









:max_bytes(150000):strip_icc()/VWH-GettyImages-2059065209-7ab09bdd0be8409493ace4364fccf792.jpg)












